Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Time-course hypoxia incubation (1% O2) of D283-Med medulloblastoma cells

ABSTRACT: Time-course hypoxia incubation (1% O2) of D283-Med medulloblastoma cells

PROVIDER: PRJNA418498 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Time-course hypoxia incubation (1% O2) of D283-Med medulloblastoma cells

Project description:Elucidation of the impact of hypoxia in D283-Med (medulloblastoma Homo sapiens, human, ATCC® HTB-185™) cells to depict molecular mechanisms, which could explain drug resistance when cells are exposed to long-term hypoxia (5 days). Global gene expression study by microarray analysis to allow an efficient search for a range of genes. D283-MED cells were incubated for a varied hypoxic duration (0, 6, 64 and 96 hours in triplicate), cDNA samples were prepared and sent directly to NimbleGen.

2017-11-16 | GSE106959 | GEO

Transcriptomic analysis of MYC-inhibited Medulloblastoma-derived D283 Med cells

Project description:Transcriptomic analysis of MYC-inhibited Medulloblastoma-derived D283 Med cells

| PRJNA718454 | ENA

D283 MED, a cell line derived from peritoneal metastatic medulloblastoma — a good choice for missing protein discovery

Project description:Our goal is the identification of more and more missing proteins from cancer cell lines. This project focuses on D283 med and U-118mg cell lines which contribute to 12 missing protein identification.

2020-11-26 | PXD021482 | Pride

D283 MED, a cell line derived from peritoneal metastatic medulloblastoma — a good choice for missing protein discovery

2021-06-21 | MSV000087678 | MassIVE

Transcriptomic analysis of MYC-inhibited Medulloblastoma-derived D283 Med cells

Project description:Medulloblastoma is one of the most common malignant pediatric brain tumors. Group 3 is the most aggressive molecular subgroup, showing the highest rate of metastasis at diagnosis. To date, very few long noncoding RNAs have been implicated in Group 3 Medulloblastoma biology. Here, we identified the long noncoding RNAs dependent on the activity of the MYC oncogene, the major driver gene of Group 3 Medulloblastoma.

2021-08-11 | GSE171117 | GEO

Identification of lncMB3-dependent transcriptome in MYC-amplified D283 Med cells.

Project description:Medulloblastoma (MB) stands as the most prevalent malignant pediatric tumor affecting the central nervous system. Categorized into four primary subgroups, each with distinct biological and clinical features, MB presents unique therapeutic implications. Group 3 (G3) and 4 (G4) MBs collectively account for the majority of cases (60%) and exhibit the highest degree of aggressiveness. However, these subgroups remain poorly characterized from a biochemical perspective. Therefore, it is crucial to unveil the fundamental molecular mechanisms underlying G3 e G4 MBs to deepen our overall comprehension of these specific conditions and to pave the way for precision medicine-driven approaches. Compared to normal human cerebella, the MYC-dependent lncRNA MB3 was found to be induced in G3-derived cell lines expressing the proto-oncogene and upregulated in G3-MB primary tumors. Consistently, LncMB3 is downregulated upon MYC inhibition and in vitro studies reveal its potent anti-apoptotic activity. To dissect the molecular network through which LncMB3 operates in MB carcinogenesis, we initiated the identification of its target genes by analyzing through RNA-Sequencing the alteration of the transcriptome following LncMB3 knockdown in G3 MB cell lines, achieved through transfections of antisense Locked Nucleic Acid (LNA) oligonucleotides (GapmeRs). Here we provide the data of three polyA+ RNA samples derived from lncMB3 knockdown (KD) and 3 control samples from the MYC-amplified D283 Med cell line that were subjected to RNA-Seq analysis.

2025-09-30 | GSE277976 | GEO

Identification of lncMB3 RNA interactome through lncMB3 Native RNA Pulldown in MYC-amplified D283 Med cells.

Project description:Medulloblastoma (MB) stands as the most prevalent malignant pediatric tumor affecting the central nervous system. Categorized into four primary subgroups, each with distinct biological and clinical features, MB presents unique therapeutic implications. Group 3 (G3) and 4 (G4) MBs collectively account for the majority of cases (60%) and exhibit the highest degree of aggressiveness. However, these subgroups remain poorly characterized from a biochemical perspective. Therefore, it is crucial to unveil the fundamental molecular mechanisms underlying G3 e G4 MBs to deepen our overall comprehension of these specific conditions and to pave the way for precision medicine-driven approaches. Compared to normal human cerebella, the MYC-dependent lncRNA MB3 was found to be induced in G3-derived cell lines expressing the proto-oncogene and upregulated in G3-MB primary tumors. Consistently, LncMB3 is downregulated upon MYC inhibition and in vitro studies reveal its potent anti-apoptotic activity. To deepen the study of the LncMB3 molecular mechanism, we employed native RNA Pulldown assays followed by RNA-Sequencing to identify LncMB3 interactome. Here we provide the data of polyA+ RNA samples derived from two biological replicates of LncMB3 Native RNA Pulldown sample sets (INPUT, EVEN, ODD, LacZ) derived from the MYC-amplified D283 Med cell line that were subjected to RNA-Seq analysis.

2025-10-02 | GSE278666 | GEO

Identification of lncMB3-dependent transcriptome in MYC-amplified D283 Med cells.

Project description:Identification of lncMB3-dependent transcriptome in MYC-amplified D283 Med cells.

| PRJNA1165133 | ENA

Identification of lncMB3 RNA interactome through lncMB3 Native RNA Pulldown in MYC-amplified D283 Med cells.

Project description:Identification of lncMB3 RNA interactome through lncMB3 Native RNA Pulldown in MYC-amplified D283 Med cells.

| PRJNA1168168 | ENA

MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma

Project description:The expression of miR-592 was found to reduce the malignant potential of Group 3 medulloblastoma cell lines, D283, D425 and HD-MB03. RNA-seq analysis was carried out to identify genes differentially expressed upon miR-592 expression in the medulloblastoma cell lines. MiR-592 expression was found to upregulate mTOR and ERK1/ERK2 signaling and bring about neuronal differentiation in D283 and D425 cells. Transcriptome sequencing was also carried out on the RNA extracted from the polyclonal population of D283 and D425 expressing miR-592 as well as the vector control population cells treated with rapamycin or U0126, a MAPK inhibitor to study if the mTOR signaling or MAPK signaling is instrumental in bringing about the neuronal differentiation.

2021-08-26 | GSE147145 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data